Nicotinamide Phosphoribosyltransferase in Human Diseases
- *Corresponding Author:
- Dr. Shui Qing Ye, MD, PhD
Departments of Pediatrics
Children’s Mercy Hospitals and Clinics
University of Missouri-School of Medicine
2401 Gillham Road, PRC/4th FL
Kansas City, MO 64108
E-mail: [email protected]
Received Date: November 15, 2010; Accepted Date: December 07, 2010; Published Date: January 07, 2011
Citation: Zhang LQ, Heruth DP, Ye SQ (2011) Nicotinamide Phosphoribosyltransferase in Human Diseases. J Bioanal Biomed 3: 013-025. doi: 10.4172/1948-593X.1000038
Copyright: © 2011 Zhang LQ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Nicotinamide phosphoribosyltransferase (NAMPT) was first reported as a pre-B-cell colony enhancing factor in 1994 with little notice, but it has received increasing attention in recent years due to accumulating evidence indicating that NAMPT is a pleiotropic protein such as a growth factor, a cytokine, an enzyme and a visfatin. Now, NAMPT has been accepted as an official name of this protein. Because of NAMPT’s multiple functions in a variety of physiological processes, their dysregulations have been implicated in the pathogenesis of a number of human diseases or conditions such as acute lung injury, aging, atherosclerosis, cancer, diabetes, rheumatoid arthritis and sepsis. This review will cover the current understanding of NAMPT’s structure and functions with an emphasis on recent progress of nicotinamide phosphoribosyltransferase’s pathological roles in various human diseases and conditions. Future directions on exploring its Terra incognita will be offered in the end.